MHC

TFS Financial Corporation Declares Dividend

Retrieved on: 
torsdag, maj 30, 2024
Banking, Professional Services, Finance, Security (finance), Love, News, Third Federal S&L, TFS, Trust, Annual report, Federal Reserve Bank, MHC, Multimedia, Bank

TFS Financial Corporation (NASDAQ: TFSL) (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland (the “Association”), today announced that the Board of Directors declared a quarterly cash dividend of $0.2825 per share, payable on June 25, 2024, to stockholders of record on June 11, 2024.

Key Points: 
  • TFS Financial Corporation (NASDAQ: TFSL) (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland (the “Association”), today announced that the Board of Directors declared a quarterly cash dividend of $0.2825 per share, payable on June 25, 2024, to stockholders of record on June 11, 2024.
  • Founded in Cleveland in 1938 as a mutual association by Ben and Gerome Stefanski, Third Federal’s mission is to help people achieve the dream of home ownership and financial security.
  • It became part of a public company in 2007 and celebrated its 85th anniversary in May 2023.
  • These forward-looking statements involve risks and uncertainties that could cause the Company’s results to differ materially from management’s current expectations.

Mutual Holding Company for TFS Financial Corporation To Seek Member Approval for Dividend Waivers

Retrieved on: 
torsdag, maj 30, 2024
Banking, Other Professional Services, Professional Services, Finance, Security (finance), American Dream, Parent, Love, News, Third Federal S&L, Federal Reserve, TFS, Trust, Annual report, Federal, MHC, Multimedia, Failure, Holding company

TFS Financial Corporation (Nasdaq: TFSL), (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland, announced that Third Federal Savings and Loan Association of Cleveland, MHC, (the “MHC”), the mutual holding company that owns 80.9% of the Company’s outstanding common stock, will hold a special meeting of its members.

Key Points: 
  • TFS Financial Corporation (Nasdaq: TFSL), (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland, announced that Third Federal Savings and Loan Association of Cleveland, MHC, (the “MHC”), the mutual holding company that owns 80.9% of the Company’s outstanding common stock, will hold a special meeting of its members.
  • All dividends on the Company’s common stock are declared at the discretion of the Company’s Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240530012821/en/
    Chairman and CEO Marc A. Stefanski (Photo: Business Wire)
    Federal Reserve Regulation MM, 12 C.F.R.
  • A failure to obtain the waiver will likely result in a reduction in the dividend expected to be paid to public stockholders.

Comprehensive Healthcare and Central Washington University Revitalize Mental Health Counseling Graduate Program, Bringing More Support to Local Communities

Retrieved on: 
tisdag, maj 28, 2024
Mental Health, Other Health, Health, University, Education, Partnership, Doctor of Philosophy, LMHC, Faculty, Mental, Learning, Organization, Student, Comprehensive, Workforce, Book, Mental health, Psychology, Central Washington University, Attention, Curriculum, MHC, CWU, Joint Commission, Multimedia, Counselor, Nursing

Today, Comprehensive Healthcare and Central Washington University (CWU) announced a significant initiative to help fill the gap of behavioral health specialists in the region.

Key Points: 
  • Today, Comprehensive Healthcare and Central Washington University (CWU) announced a significant initiative to help fill the gap of behavioral health specialists in the region.
  • In recent years, community behavioral health organizations have experienced a significant workforce shortage and have been challenged to meet the increasing demand for mental health services in local communities.
  • The program’s in-depth training will prepare CWU’s graduate MHC students to provide a broad range of comprehensive, ethical, and culturally relevant behavioral health services within their communities.
  • “Central Washington University would like to express our sincere gratitude to Comprehensive Healthcare for this generous, and much-needed, donation,” CWU President Jim Wohlpart said.

Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
Immune tolerance, Prognosis, Master, ILT4, Flow cytometry, Pembrolizumab, Anemia, WT, HPV, Colorectal cancer, NK, University, Clinical trial, PFS, Therapy, Neoplasm, Disease, EGFR, Safety, SAN, Head, ILT2, Irinotecan, PD-1, Growth, Bevacizumab, Cancer, Incidence, ASCO, Associate, MHC, Consultant, Woman, Society, Fatigue, BRAF, Cetuximab, Tizona, Immunotherapy, Oxaliplatin, DCR, Combination therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC). The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC).
  • The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.
  • “Metastatic colorectal cancer is a global health issue, affecting men and women equally and with rising incidence among young adults.
  • “These Phase 1b clinical results boost our confidence that TTX-080 in combination with cetuximab may improve clinical outcomes in patients with biomarker-defined advanced colorectal cancer and head and neck squamous cell carcinoma,” said Swami Murugappan, M.D., Ph.D., Consulting Chief Medical Officer at Tizona Therapeutics.

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Retrieved on: 
onsdag, maj 15, 2024
ASX, Patient, CD4, Plasma, MBC, Pharmacodynamics, Safety, Autoimmune disease, RECIST, IMM, Poster, Congress, Blood, CDK, Cancer, Eftilagimod alpha, MHC, Paclitaxel, ESMO, Oncology, CD8, TNBC, Gamma ray, MHC class II, Pharmaceutical industry

SYDNEY, AUSTRALIA, May 15, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha (“efti”), a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel.

Key Points: 
  • During the immuno-oncology (IO)-chemotherapy treatment of efti and paclitaxel, this patient achieved a partial response (PR) that subsequently turned into a CR.
  • As of the data cut-off (April 3), no dose-limiting toxicities and no treatment-emergent adverse events of grade 3 or higher severity were recorded.
  • Further data updates in terms of safety and efficacy from AIPAC-003 are expected in CY2024.
  • The ESMO Breast 2024 poster will be available on the Posters & Publications section of Immutep’s website.

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Retrieved on: 
fredag, maj 17, 2024
Infectious Diseases, FDA, Entertainment, Clinical Trials, Biotechnology, Health, Pharmaceutical, Oncology, Podcast, Partnership, Patient, American Urological Association, News, AUA, Bladder cancer, NK, Bacillus, University, MD Anderson Cancer Center, SII, Research, Cancer, MHC, CIS, BCG, NMIBC, MBBS, Annual general meeting, Vaccine

“The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.

Key Points: 
  • “The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.
  • These MHC-negative cells are the exact target for natural killer cells which ANKTIVA activates.
  • ANKTIVA, a first-in-class IL-15 receptor agonist, received approval from the FDA on April 22 for the treatment of patients with BCG-unresponsive NMIBC CIS.
  • ANKTIVA’s unique mechanism of action activates the body’s natural killer cells and killer T-cell immune system to attack tumor cells.

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Retrieved on: 
torsdag, maj 2, 2024
Oncology, Health, Other Health, General Health, Research, Science, Pharmaceutical, FDA, Cancer, Safety, CD4, Serum, Carcinoma in situ, MHC, Grand Bahama International Airport, Vaccine, BCG, SII, Merck & Co., CIS, Patient, Medicine, NMIBC, Standard of care, Neoplasm, GMP, Bladder cancer, Serum Institute of India, CD8, Escape Room

ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).
  • Increasing the available supply of BCG is intended to address shortages for the combination therapy with ANKTIVA.
  • “The collaboration between Serum Institute of India and ImmunityBio will undoubtedly transform the way we approach cancer treatment.
  • We look forward to exploring ANKTIVA in combination with BCG in non-muscle invasive bladder cancer (NMIBC) and across other tumor types.

Lake Shore Bancorp, Inc. Declares First Quarter 2024 Dividend

Retrieved on: 
fredag, april 26, 2024
Federal Reserve Bank, MHC, Reserve Bank, Holding company

DUNKIRK, N.Y., April 26, 2024 (GLOBE NEWSWIRE) -- Lake Shore Bancorp, Inc. (the “Company”) (NASDAQ: LSBK), the holding company for Lake Shore Savings Bank (the “Bank”), announced yesterday that it received the written approval from the Federal Reserve Bank of Philadelphia (the “Reserve Bank”) to pay a cash dividend of $0.18 per share to its stockholders.

Key Points: 
  • DUNKIRK, N.Y., April 26, 2024 (GLOBE NEWSWIRE) -- Lake Shore Bancorp, Inc. (the “Company”) (NASDAQ: LSBK), the holding company for Lake Shore Savings Bank (the “Bank”), announced yesterday that it received the written approval from the Federal Reserve Bank of Philadelphia (the “Reserve Bank”) to pay a cash dividend of $0.18 per share to its stockholders.
  • As the Company has previously disclosed, the MHC received the approval of its members (depositors of Lake Shore Savings Bank) for the Dividend Waivers on April 2, 2024.
  • On April 25, 2024, the Board of Directors declared a cash dividend of $0.18 per share on its outstanding common stock.
  • The dividend is expected to be paid on May 10, 2024 to stockholders of record as of May 6, 2024.

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit

Retrieved on: 
tisdag, april 23, 2024
TCE, MHC, Antibody

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

Key Points: 
  • ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
  • The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy.

Lake Shore Bancorp, Inc. Announces 2024 First Quarter Financial Results

Retrieved on: 
måndag, april 22, 2024
Sale, Total, Federal Home Loan Banks, Federal Reserve Bank, Insurance, Bank, Marketing, MHC, FDIC

2024 First Quarter Financial Highlights:

Key Points: 
  • 2024 First Quarter Financial Highlights:
    Total deposits increased by $3.8 million, or 0.6% since December 31, 2023.
  • Net interest income for the 2024 first quarter decreased $1.2 million, or 18.4%, to $5.1 million as compared to $6.3 million for the 2023 first quarter.
  • Interest income for the 2024 first quarter was $8.6 million, an increase of $658,000, or 8.3%, compared to $8.0 million for the 2023 first quarter.
  • Interest expense for the 2024 first quarter was $3.5 million, an increase of $1.8 million, or 109.4%, from $1.7 million for the 2023 first quarter.